



Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
		Applicant Shuang Liu	
		Filing Date March 18, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
CA	1	Abeyasinghe, R.D., et al., "The environment of the lipoxygenase iron binding site explored with novel hydroxypyridine iron chelators," <i>J. of Biological Chem.</i> , 1996, 271(44), 7965-7972	
CA	2	Ahmed, S.I., et al., "The structures of bis-maltolato-zinc(II) and of bis-3-hydroxy-1,2-dimethyl-4-pyridinonato-zinc(II) and-lead(II)," <i>Polyhedron</i> , 2000, 19, 129-135	
CA	3	Barret, M.C., et al., "Synthesis and structural characterization of Tin(II) and Zinc(II) derivatives of cyclic α -hydroxyketones, including the structures of Sn(mltol) ₂ , Sn(tropolone) ₂ , Zn(tropolone) ₂ , and Zn(hinokitiol) ₂ ," <i>Inorg. Chem.</i> , 2001, 40, 4384-4388	
CA	4	Bebbington, D., et al., "3,5-disubstituted-4-hydroxyphenyls linked to 3-hydroxy-2-methyl-4(1H)-pyridinone: potent inhibitors of lipid peroxidation and cell toxicity," <i>J. Med. Chem.</i> , 2000, 43, 2779-2782	
CA	5	Bickerdike, M.J., et al., "Enhanced acetylcholine release in striatum after chronic amphetamine is NMDA-dependent," <i>NeuroReport</i> , 1999, 10, 77-80	
CA	6	Bosquet, J.-C., et al., "Gd-DOTA: characterization of a new paramagnetic complex," <i>Radiology</i> , 1988, 166, 693-698	
CA	7	Brannen, A.L., et al., "Use of antioxidants in self-preserving cosmetic and drug formulations," <i>Cosmet. Sci. Technol. Ser.</i> , 1997, 16, 159-179	
CA	8	Brewer, G.J., "Cooper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's Disease," <i>Exp. Biol. Med.</i> , 2001, 226(7), 665-673	
CA	9	CAPLUS Accession No. 1995:887972 (English abstract of Japanese Patent)	
CA	10	Caravan, P., et al., "Gadolinium(III) chelates as MRI contrast agents: structure, dynamics and applications," <i>Chem. Rev.</i> , 1999, 99, 2293-2352	
EXAMINER		AWLAKH	DATE CONSIDERED 2-4-05

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
		Applicant Shuang Liu	
		Filing Date March 18, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
CA	11	Caravan, P., et al., "Reaction chemistry of BMOV, Bis(maltolato)oxovanadium(IV)—apotent insulin mimetic agent," <i>J. Am. Chem. Soc.</i> , 1995 , <i>117</i> , 12759-12770	
CA	12	Clarke, E.T., et al., "Stabilities of 1,2-dimethyl-3-hydroxy-4-pyridinone chelates of divalent and trivalent metal ions," <i>Inorganica Chimica Acta</i> , 1992 , <i>191</i> , 57-63	
CA	13	Dobbin, P.S., et al., "Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1 <i>H</i>)-pyridinones: orally active iron chelators with clinical potential," <i>J. Med. Chem.</i> , 1993 , <i>36</i> , 2448-2458	
CA	14	Dutt, N.K., et al., "Chemistry of lanthanons—XL1. isolation and characterization of tris chelates of lanthanides with maltol, kojic acid and chloro-kojic acid," <i>J. Inorg. Nucl. Chem.</i> , 1975 , <i>37</i> , 1801-1802	
CA	15	Edwards, D.S., et al., "Characterization of Tris(N-substituted-2-methyl-3-hydroxy-4-pyridinonato)technetium(IV)cations," <i>Inorg. Chem.</i> , 1994 , <i>33</i> , 5607-5609	
CA	16	Edwards, D.S., et al., "Potential ^{99m} Tc radiopharmaceuticals for renal imaging: tris(N-substituted-3-hydroxy-2-methyl-4-pyridinonato)technetium(IV)cations," <i>Nucl. Med. Biol.</i> , 1993 , <i>20</i> (7), 857-863	
CA	17	El-Jammal, A., et al., "Cooper complexation by 3-hydroxypyridin-4-one iron chelators: structural and iron competition studies," <i>J. Med. Chem.</i> , 1994 , <i>37</i> , 461-466	
CA	18	Ellis, B.L., et al., "6-alkoxymethyl-3-hydroxy-4H-pyranones: potential ligands for cell-labeling with indium," <i>Eur. J. Nucl. Med.</i> , 1999 , <i>26</i> , 1400-1406	
CA	19	Ellis, B.L., et al., "Synthesis, physicochemical properties, and biological evaluation of hydroxypyranones and hydroxypyridinones: novel bidentate ligands for cell-labeling," <i>J. med. Chem.</i> , 1996 , <i>39</i> , 3659-3670	
CA	20	Faller, B., et al., "Improving the oral bioavailability of the iron chelator HBED by breaking the symmetry of the intramolecular H-bond network," <i>J. Med. Chem.</i> , 2000 , <i>43</i> , 1467-1475	
EXAMINER		ASLAKH	DATE CONSIDERED 2-4-05

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
		Applicant Shuang Liu	
		Filing Date March 18, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
CA	21	Fernandez, J.A., et al., "Essential viral and cellular zinc and iron containing metalloproteins as targets for novel antiviral and anticancer agents: implications for prevention and therapy of viral diseases and cancer," <i>Anticancer Res.</i> , 2001, 21, 931-958	
CA	22	Ferrali, M., et al., "3-hydroxy-(4H)-benzopyran-4-ones as potential iron chelating agents in vivo," <i>Bioorganic & Medicinal Chem.</i> , 2001, 9, 3041-3047	
CA	23	Foda, H.D., et al., "Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis," <i>DDT</i> , 2001, 9, 478-482	
CA	24	Gutteridge, J.M.C., et al., "Iron toxicity and oxygen radicals," <i>Ballièr's Clin. Haematology</i> , 1989, 2(2), 195-256	
CA	25	Gwyn, K., et al., "Breast cancer during pregnancy," <i>Oncology</i> , 2001, 15(1), 39-46	
CA	26	Hashimoto, M., et al., "Oxidative stress induces amyloid-like aggregate formation of NACP/ α -synuclein in vitro," <i>NeuroReport</i> , 1999, 10, 717-721	
CA	27	Henrotin, Y., et al., "The inhibition of metalloproteinases to treat osteoarthritis: reality and new perspectives," <i>Expert Opin. Ther. Patents</i> , 2002 12(1), 29-43	
CA	28	Hidalgo, M., et al., "Development of matrix metalloproteinase inhibitors in cancer therapy," <i>J. of the National Cancer Institute</i> , 2001, 93(3), 178-193	
CA	29	Hider, R.C., et al., "Design of orally active iron chelators," <i>Acta Haematol</i> , 1996, 95, 6-12	
CA	30	Hu, T.C.-C., et al., "Manganese-enhanced MRI of mouse heart during changes in inotropy," <i>Magnetic Resonance in Medicine</i> , 2001, 46, 884-890	
EXAMINER		AULAKH	DATE CONSIDERED 2-4-05

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
		Applicant Shuang Liu	
		Filing Date March 18, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
CA	31	Hunter, D.R., et al., "Comparison of Ca^{2+} , Sr^{2+} , and Mn^{2+} fluxes in mitochondria of the perfused rat heart," <i>Circ. Res.</i> , 1980, 47, 721-727	
CA	32	John A., et al., "The role of matrix metalloproteinases in tumor angiogenesis of tumor metastasis," <i>Pathology Oncology Res.</i> , 2001, 7(1), 14-23	
CA	33	Liu, Z.D., et al., "Design, synthesis and evaluation of <i>N</i> -basis substituted 3-hydroxypyridin-4-ones: orally active iron chelators with lysosomotropic potential," <i>J. Pharm. Pharmacol.</i> , 2000, 52, 263-272	
CA	34	Liu, Z.D., et al., "Structure-activity investigation of the inhibition of 3-hydroxypyridin-4-ones on mammalian tyrosine hydroxylase," <i>Biochem. Pharmac.</i> , 2001, 285-290	
CA	35	Liu, Z.D., et al., "Synthesis of 2-amido-3-hydroxypyridin-4(1 <i>H</i>)-ones: novel iron chelators with enhanced pFe^{3+} values," <i>bioorganic & Medicinal Chem.</i> , 2001, 9, 563-573	
CA	36	Magerstädt, M., et al., "Gd(DOTA): an alternative to Gd(DTPA) as a $T_{1,2}$ relaxation agent for NMR imaging or spectroscopy," <i>Magnetic Resonance in Medicine</i> , 1986, 3, 808-812	
CA	37	Martell, A.E., et al., "New chelating agents suitable for the treatment of iron overload," <i>Inorganica Chimica Acta</i> , 1999, 291, 238-246	
CA	38	Matthews, A.J., et al., "Iron and atherosclerosis: inhibition by the iron chelator deferiprone (L1)," <i>J. of Surg. Res.</i> , 1997, 73, 35-40	
CA	39	McCawley, L.J., et al., "Matrix metalloproteinases: multifunctional contributors to tumor progression," <i>Molecular Medicine Today</i> , 2000, 6, 149-156	
CA	40	McNeill, J.H., et al., "Bis(maltolato)oxovanadium(IV) is a potent insulin mimic," <i>J. Med. Chem.</i> , 1992, 35, 1489-1491	
EXAMINER		AULAKH	DATE CONSIDERED 2-4-05

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
		Applicant Shuang Liu	
		Filing Date March 18, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
CA	41	Melchoir, M., et al., "Vanadium complexes as insulin mimetic agents: coordination chemistry and in vivo studies of oxovanadium(IV) and dioxovanadate(V) complexes formed from naturally occurring chelating oxazolate, thiazolate, or picolinate units," <i>Inorg. Chem.</i> , 1999 , 38, 2288-2293	
CA	42	Molenda, J.J., et al., "Enhancement of iron excretion via monoanionic 3-hydroxypyrid-4-ones," <i>J. Med. Chem.</i> , 1994 , 37, 93-98	
CA	43	Narita, K., et al., "Mn and Mg influxes through Ca channels of motor nerve terminals are prevented by verapamil in frogs," <i>Brain Res.</i> , 1990 , 510, 289-295	
CA	44	Naughton, D.P., et al., "EDTA bis-(ethyl phenylalaninate): a novel transition metal-ion chelating hydroxyl radical scavenger with a potential anti-inflammatory role," <i>Bioorganic & Medicinal Chem. Letts.</i> , 2001 , 11, 2573-2575	
CA	45	Piyamongkol, S., et al., "Novel synthetic approach to 2-(1'-hydroxyalkyl)-and 2-amido-3-hydroxypyridin-4-ones," <i>Tetrahedron</i> , 2001 , 57, 3479-3486	
CA	46	Porter, J.B., "A risk-benefit assessment of iron-chelation therapy," <i>Drug Safety</i> , 1997 , 17(6), 407-421	
CA	47	Rai, B.L., et al., "Synthesis, physicochemical properties and biological evaluation of ester prodrugs of 3-hydroxypyridin-4-ones: design of orally active chelators with clinical potential," <i>Eur. J. Med. Chem.</i> , 1999 , 34, 475-485	
CA	48	Rai, B.L., et al., "Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones," <i>J. Med. Chem.</i> , 1998 , 41, 3347-3359	
CA	49	Rangel, M., "Pyridinone oxovanadium(IV) complexes: a new class of insulin mimetic compounds," <i>Transition Metal Chem.</i> , 2001 , 26, 219-223	
CA	50	Remington's Pharmaceutical Sciences, 17 th Ed., <i>Mack Publishing Co.</i> , 1985 , page 1418	
EXAMINER		AULAKH	DATE CONSIDERED 2-4-05

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
		Applicant Shuang Liu	
		Filing Date March 18, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
CA	51	Runge, V.M., "Safety of approved MR contrast media for intravenous injection," <i>J. of Magnetic Resonance Imaging</i> , 2000, 12, 205-213	
CA	52	Runge, V.M., et al., "MR imaging of rat brain glioma: Gd-DTPA versus Gd-DOTA," <i>Radiology</i> , 1988, 166, 835-838	
CA	53	Sakurai, H., et al., "Cysteine methyl ester-oxovanadium(IV) complex, preparation and characterization," <i>Inorganica Chimica Acta</i> , 1980, 46, L119-L120	
CA	54	Shibuya, I., et al., "Indications from Mn-quenching of fura-2 fluorescence in melanotrophs that dopamine and baclofen close Ca channels that are spontaneously open by not those opened by high $[K^+]_o$, and that Cd preferentially blocks the latter," <i>Cell Calcium</i> , 1993, 14, 33-44	
CA	55	Singh, S., et al., "Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones," <i>Drug Metabolism and Disposition</i> , 1992, 20(2), 256-261	
CA	56	Skiles, J.W., et al., "The design, structure and therapeutic application of matrix metalloproteinase inhibitors," <i>Curr. Med. Chem.</i> , 2001, 8, 425-474	
CA	57	Streater, M., et al., "Novel 3-hydroxy-2(1H)-pyridinones. Synthesis, iron(III)-chelating properties, and biological activity," <i>J. Med. Chem.</i> , 1990, 33, 1749-1755	
CA	58	Thomas, et al., "Chemotherapeutic studies in the heterocyclic series. Reaction of kojic acid with hydrazine. Reaction of kojic acid ethers with hydrazine," <i>Helvetica Chimica Acta</i> , 1960, 43, 469-477	
CA	59	Thompson, K.H., et al., "Coordination chemistry of vanadium in metallopharmaceutical candidates compounds," <i>Coordination Chem. Rev.</i> , 2001, Vol. 219-221, 1033-1053	
CA	60	Thompson, K.H., et al., "Design of vanadium compounds as insulin enhancing agents," <i>J. Chem. Soc., Dalton Trans.</i> , 2000, 2885-2892	
EXAMINER		AWLAKH	DATE CONSIDERED 2-4-05

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office		Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
		Applicant Shuang Liu	
		Filing Date March 18, 2004	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
CA	61	Whittaker, M., et al., "Design and therapeutic application of matrix metalloproteinase inhibitors," <i>Chem. Rev.</i> , 1999, 99, 2735-2776	
CA	62	Yuen, V.G., et al., "Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration," <i>Can. J. of Physiol. Pharmacol.</i> , 1995, 73, 55-64	
CA	63	Yuen, V.G., et al., "Glucose-lowering properties of vanadium compounds: comparison of coordination complexes with maltol or Kojic acid as ligands," <i>J. of Inorganic Biochem.</i> , 1997, 68, 109-116	
CA	64	Yuen, V.G., et al., "Effects of low and high dose administration of bis(maltolato)oxovanadium(IV) on <i>fa/fa</i> Zucker rats," <i>Can. J. Physiol. Pharmacol.</i> , 1996, 74, 1001-1009	
CA	65	Zhang, Z., et al., "Potential ⁶⁷ Ga radiopharmaceuticals for myocardial imaging: Tris(1-aryl-3-hydroxy-2-methyl-4-pyridinonato)gallium(III) complexes," <i>Nucl. Med. Biol.</i> , 1992, 19(3), 327-335	
CA	66	Dobbin, P.S., et al., "Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential," <i>J. Med. Chem.</i> , 1993, 36, 2448-2458	
CA	67	Edwards, D.S., et al., "Characterization of Tris(N-substituted-2-methyl-3-hydroxy-4-pyridinonato)technetium(IV) cations," <i>Inorg. Chem.</i> , 1994, 33, 5607-5609	
CA	68	Melchior, M., "Vanadium complexes as insulin mimetic agents: coordination chemistry and in vivo studies of oxovanadium(IV) and dioxovanadate(V) complexes formed from naturally occurring chelating oxazolate, thiazolate, or picolinate units," <i>Inorg. Chem.</i> , 1999, 38, 2288-2293	
CA	69	Rai, B.L., et al., "Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones," <i>J. Med. Chem.</i> , 1998, 41, 3347-3359	
EXAMINER		AWLAKH	DATE CONSIDERED 2-4-05

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
	Applicant Shuang Liu	
	Filing Date March 18, 2004	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
CA	70	4,908,371	03/13/90	Moerker, et al.	514	318
CA	71	5,087,440	02/11/92	Cacheris, et al.	424	9
CA	72	5,155,215	10/13/92	Ranney	534	16
CA	73	5,256,676	10/26/93	Hider, et al.	514	348
CA	74	5,525,326	06/11/96	Unger	424	9.36
CA	75	5,527,790	06/18/96	McNeill, et al.	514	186
CA	76	5,688,815	11/18/97	Zbinden, et al.	514	348
CA	77	5,716,598	02/10/98	Golman, et al.	424	9.36
CA	78	5,866,563	02/02/99	McNeil, et al.	514	186
CA	79	5,877,210	03/02/99	Schieven	514	492
CA	80	5,980,863	11/09/99	Harnish, et al.	424	9.36
CA	81	6,046,219	04/04/00	Hanauske-Abel, et al.	514	348
CA	82	6,294,152 B1	09/25/01	Davies, et al.	424	9.361
CA	83	6,323,340 B1	05/15/01	Zhang, et al.	514	492
CA	84	2,136,807	11/15/38	Stoker	110	48
CA	85	6,232,340	05/15/01	Zhang, et al.	514	492

EXAMINER

AWLAKH

DATE CONSIDERED

2-4-05

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
	Applicant Shuang Liu	
	Filing Date March 18, 2004	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
CA	86	WO 91/12822	09/05/91	PCT		
CA	87	WO 93/10822	06/10/93	PCT		
CA	88	WO 96/05867	02/29/96	PCT		
CA	89	WO 96/22021	07/25/96	PCT		
CA	90	WO 96/41639	12/27/96	PCT		
CA	91	WO 97/02842	01/30/97	PCT		
CA	92	WO 98/54138	12/03/98	PCT		
CA	93	WO 99/23075	05/14/99	PCT		
CA	94	WO 99/30562	06/24/99	PCT		
CA	95	WO 00/16736	03/30/00	PCT		
CA	96	WO 00/16782	03/30/00	PCT		
CA	97	WO 00/24730	05/04/00	PCT		
CA	98	WO 01/12168	02/22/01	PCT		
CA	99	0 335 745	10/04/89	EPO		
CA	100	1 006 108	06/07/00	EPO		
CA	101	1 006 112	06/07/00	EPO		
CA	102	2 269 589	02/16/94	UK		
EXAMINER <i>ALLAKH</i>				DATE CONSIDERED <i>2-4-05</i>		

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. BMS-2601/ PH7384 DIV	Application No. 10/803,724
	Applicant Shuang Liu	
	Filing Date March 18, 2004	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
CA	103	2 345 058	06/28/00	UK		
CA	104	07 179 474	07/18/95	JP		
CA	105	WO 98/01458	01/15/98	PCT	X abstract	
CA	106	0 316 279 A2	05/17/89	EP	X abstract	
EXAMINER		ALUAKM		DATE CONSIDERED 2-4-05		